Polynuclear Silver(I)–Quinoxaline Complex: Comprehensive Structural Characterization, Antimycobacterial Properties and DNA/BSA Binding Study

Read full text
Authors: Ghada Bouz, Nevena L. Stevanović, Marta Počkaj, Tina P. Andrejević, Iztok Turel, Ondřej Jand’ourek, Klára Konečná, Žiko Milanović, Kristina Milisavljević, Biljana Đ. Glišić
Cited by: 2
References: 64

Abstract

Background: Silver(I) complexes with aromatic heterocyclic ligands are well known for their broad antimicrobial potential, largely attributed to their ability to interact with biomolecular targets. Results and Discussion: In this study, a new polynuclear silver(I) complex with N-(3′-phenylpropyl)quinoxaline-2-carboxamide (pqx-2ca), [Ag(NO3)(pqx-2ca)]n, was synthesized. Its structure was confirmed by single-crystal X-ray diffraction and comprehensively characterized using NMR, IR, and UV–Vis spectroscopy, while its behavior in solution was further elucidated through density functional theory (DFT) calculations combined with spectral simulations. The complex demonstrated significantly enhanced antimycobacterial activity compared with the free ligand when tested against the avirulent Mycobacterium tuberculosis H37Ra, fast-growing model organisms M. smegmatis and M. aurum, as well as the nontuberculous species M. avium and M. kansasii. Experimental and docking studies confirmed stable binding of the complex to subdomain III of bovine serum albumin (BSA) and to the minor groove of DNA. Furthermore, docking to validated mycobacterial targets revealed inhibitory potential toward the InhA and MmpL3 proteins, with binding affinities comparable to those of standard inhibitors. Conclusions: These results highlight [Ag(NO3)(pqx-2ca)]n as a promising candidate for the development of silver-based antimycobacterial agents with a dual mechanism of action involving both DNA and protein targets.

Fields of Study & Subjects

Metal complexes synthesis and properties Protein Interaction Studies and Fluorescence Analysis Synthesis and Biological Evaluation

Publication details

Journal / source
Pharmaceutics
Publisher
MDPI AG
Volume
18
Issue
2
Pages
169–169
Publication date
27 January 2026
Language
EN